Find information on thousands of medical conditions and prescription drugs.

Eligard

Leuprolide is a gonadotropin-releasing hormone agonist (GnRH agonist). By causing constant stimulation of the pituitary GnRH receptors, it intially causes stimulation (flare), but thereafter decreases pituitary secretion (downregulation) of gonadotropins luteinizing hormone (LH) and follicle stimulating hormone (FSH). more...

 Home
Diseases
Medicines
A
B
C
D
E
E-Base
Ecstasy (drug)
Edecrin
Edrophonium
Edrophonium chloride
Efavirenz
Effexor
Eflornithine
Elavil
Eldepryl
Elidel
Eligard
Elitek
Elixomin
Elixophyllin
Ellagic acid
Elmiron
Eloxatin
Elspar
Emtriva
Emylcamate
Enalapril
Enalaprilat
Enalaprilat
Endep
Enflurane
Enoxaparin sodium
Entacapone
Enulose
Epi-pen
Epinephrine
Epirubicin
Epitol
Epivir
Epogen
Eprosartan
Ergocalciferol
Ergoloid Mesylates
Ergotamine
Eryc
Eryped
Erythromycin
Esgic
Eskalith
Esmolol
Estazolam
Estazolam
Estrace
Estraderm
Estradiol
Estradiol
Estradiol valerate
Estring
Estrogel
Estrone
Estrostep
Ethacridine
Ethambutol
Ethchlorvynol
Ethosuximide
Ethotoin
Etiracetam
Etodolac
Etopophos
Etoposide
Etorphine
Evista
Exelon
Exemestane
Hexal Australia
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Like other GnRH agonists, leuprolide may be used in the treatment of hormone-responsive cancers such as prostate cancer or breast cancer, estrogen-dependent conditions (such as endometriosis or uterine fibroids), to treat precocious puberty, and to control ovarian stimulation in IVF.

Leuprolide acetate is marketed by Bayer AG under the brand name Viadur, by Sanofi-Aventis under the brand name Eligard, and by TAP Pharmaceuticals under the brand name Lupron.

Read more at Wikipedia.org
• [List your site here Free!]

Europe: French drug firm lists in New York
From Global Finance, 9/1/02 by Platt, Gordon

French pharmaceutical company Sanofi-Synthelabo listed American depositary receipts on the NewYork Stock Exchange. Sanofi-Synthelabo is a marketing partner for Atrix laboratories, a Colorado firm that recently received US Food and Drug Administration approval for its second Eligard product for the treatment of advanced prostate cancer.

The Parisbased company's leading products are Plavix, used to prevent blood clots; Ambien, an insomnia medication; and Avapro, for the treatment of hypertension.

The acquisition of Pharmacia's 51% stake in Illinois-based Lorex Pharmaceuticals' joint venture in April 2002 gave SanofiSynthelabo full marketing rights for Ambien. Over the past three years, the company has significantly expanded its operations in the United States, where it has more than 2,000 sales representatives.

No new shares were issued in conjunction with the ADR listing. Sanofi-Synthelabo's common shares trade on Euronext Paris.

Copyright Global Finance Media Inc. Sep 2002
Provided by ProQuest Information and Learning Company. All rights Reserved

Return to Eligard
Home Contact Resources Exchange Links ebay